Tonix Pharmaceuticals Holding Corp.
TNXPTonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
Drugs in Pipeline
9
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Sep 15, 2026
15wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
FDA PDUFA Date TNX-1800 (priority)
For COVID-19. BLA filing. Extracted from SEC filing: 8-K
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
TNX-102 SL Tablet, 5.6 mg
Fibromyalgia
TNX-102 SL Tablet, 2.8mg
Fibromyalgia
TNX-102 SL Tablet 2.8 mg
Primary Fibromyalgia
TNX-102 SL
Primary Fibromyalgia
TNX-102 SL 5.6 mg
PTSD
TNX-102 SL 2.8mg
Primary Fibromyalgia
TNX-201
Tension-Type Headache
TNX-1900
Chronic Migraine
TNX-601 ER
Depression
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TNX-102 SL Tablet, 5.6 mg | Phase 3 | Fibromyalgia | - | - |
TNX-102 SL Tablet, 2.8mg | Phase 3 | Fibromyalgia | - | - |
TNX-102 SL Tablet 2.8 mg | Phase 3 | Primary Fibromyalgia | - | - |
TNX-102 SL | Phase 3 | Primary Fibromyalgia | - | - |
TNX-102 SL 5.6 mg | Phase 3 | PTSD | - | - |
TNX-102 SL 2.8mg | Phase 3 | Primary Fibromyalgia | - | - |
TNX-201 | Phase 2 | Tension-Type Headache | - | - |
TNX-1900 | Phase 2 | Chronic Migraine | - | - |
TNX-601 ER | Phase 2 | Depression | - | - |